AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase

May 28, 2026 07:20 AM EDTUpdated 02:47 PM Pharma Ab­b­Vie clinch­es FDA ap­proval for ul­tra-rare blood can­cer ADC from Im­muno­Gen pur­chase Ayisha Sharma News Reporter Ab­b­Vie said the FDA has ap­proved an an­ti­body-drug con­ju­gate it ob­tained as part of its $10.1 bil­lion buy­out of Im­muno­Gen for an … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER